ADO: Covid-19 for USA & EU, page-173

DV I can sympathize with you as I too have had to suffer the past of ADO's pursuits pre 2017 (first invested 2015).
The near death experience with the Diasource debarcle (lets buy a production platform when there was no market
for our product) changed the direction of this company in 2017 viz. the P.O.C. market. The battery thing was a bonus
albeit it is still my concern that it is still a proof of concept - 500 cycles ? @ what % silicon ?. The life sciences will be
critical to the share price if batteries don't get over the bar.

The current share price impetus is telling us something which we have not seen for years. I have let go the past and
can now envisage my future investment strategy with this company.